Telbivudine Exhibits No Inhibitory Activity against HIV-1 Clinical Isolates
            <i>In Vitro</i>

Lin, Kai; Karwowska, Sylwia; Lam, Eric C.S.; Limoli, Kay; Evans, Thomas G.; Avila, Claudio

doi:10.1128/aac.01703-09

Cited by 12 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was clearly demonstrated that, in contrast to ETV, LdT does not exert an antiviral effect against wild-type as well as drug-resistant HIV strains. These virological data are in agreement with the data from Lin et al [10], who also reported no in vitro anti-HIV activity for LdT using the single-cycle PhenoSense™ assay (Monogram Biosciences, South San Francisco, CA, USA). Finally, we clearly demonstrate that, in contrast to ETV-MP, LdT-MP is not incorporated by wild-type HIV-1 RT.…”

Section: Discussionsupporting

confidence: 92%

“…Telbivudine (LdT), also known as l-thymidine, was approved for the treatment of chronic HBV infection in 2006. LdT in its 5′-TP form (LdT-TP) was shown previously to be a specific inhibitor of the HBV polymerase and did not demonstrate in vitro activity against HIV-1 [9][10][11]. This latter finding would make LdT a suitable candidate for the treatment of HIV-HBV-coinfected individuals without risking the…”

mentioning

confidence: 99%

See 1 more Smart Citation

Telbivudine Exerts no Antiviral Activity against HIV-1 In Vitro and in Humans

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

mentioning

confidence: 99%

Telbivudine Exerts no Antiviral Activity against HIV-1 In Vitro and in Humans

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Although a slight decrease in HIV-RNA was observed,68 no HIV mutation was found in vitro,69 suggesting that the supposed ‘anti-HIV activity of LdT’ might proceed from the consequence of HBV suppression and a direct immune modulating effect of LdT 70…”

Section: Hepatitis B: Remaining Challenges In Diagnosis Treatment Anmentioning

confidence: 99%

HIV and viral hepatitis coinfections: advances and challenges

Lacombe

Rockstroh

2012

Gut

143

View full text Add to dashboard Cite

With a prevalence affecting over 30% of HIV infected patients, coinfection with hepatitis B (HBV) or C (HCV) virus remains one of the most frequent comorbidities in this population, with a significant impact in terms of morbidity and mortality associated with liver disease. Recent findings in the physiopathology of HIV in the liver have confirmed that it may contribute, along with hepatotoxicity of antiretrovirals and the burden of metabolic diseases, to a more rapid progression of liver fibrosis, especially when there is underlying chronic hepatitis coinfection. Both fields of research and clinical appraisal of HBV and HCV coinfection are rapidly evolving and prompt a change in the former paradigms of clinical care and management of chronic hepatic coinfection in the context of HIV. The advent of anti-HCV direct antiviral agents has indeed completely shaken up the treatment guidelines for HCV, and the tricky management of these new agents with antiretrovirals means referring patients to specialised centres. In HBV coinfection, therapeutic options have not changed recently but new challenges have emerged regarding the management of low replicating HBV-DNA in optimally treated patients and long term exposure to antivirals. Finally, the global increase in life expectancy in HIV infected patients has been accompanied in coinfected patients by a higher risk of emergence of end stage liver diseases for which access to orthotopic liver transplantation and innovative procedures such as targeted hepatocellular carcinoma therapies should be facilitated.

show abstract

“…43 In vitro experiments, however, have not confirmed any anti-HIV activity for LdT. 44 On the other hand, LdT is a thymidine analogue and might share the same intracellular phosphorylation pathways with zidovudine (AZT) or stavudine (d4T). Thus, its use in combination must be avoided.…”

Section: Entecavir Adefovir and Telbiduvinementioning

confidence: 99%

Hepatitis B Virus and HIV Infection

Martín-Carbonero¹,

Poveda²

2012

Semin Liver Dis

View full text Add to dashboard Cite

Approximately 5 to 10% of human immunodeficiency virus- (HIV-) infected persons worldwide have chronic hepatitis B virus (HBV). The management of these patients merits special attention. They experience a faster progression to cirrhosis and more frequent liver-related death than HBV-monoinfected individuals. For this reason, therapy for both HIV and HBV is a priority in most cases. Some antivirals (i.e., tenofovir, lamivudine, emtricitabine) are active against both viruses and should be part of the antiretroviral treatment choice. However, drugs such as entecavir, telbivudine, or adefovir are active against HBV and may display some residual activity against HIV, occasionally leading to the selection of resistance mutations in the HIV polymerase, as is clearly shown with entecavir. Thus, they should be used only in the context of potent antiretroviral treatment. In this review, the authors will provide updated information on the natural history of HIV/HBV coinfected patients, when and which drugs should be used in treatment, and the concern about selection of drug resistance and vaccine escape mutants.

show abstract

Telbivudine Exhibits No Inhibitory Activity against HIV-1 Clinical Isolates In Vitro

Cited by 12 publications

References 16 publications

Telbivudine Exerts no Antiviral Activity against HIV-1 In Vitro and in Humans

Telbivudine Exerts no Antiviral Activity against HIV-1 In Vitro and in Humans

HIV and viral hepatitis coinfections: advances and challenges

Hepatitis B Virus and HIV Infection

Contact Info

Product

Resources

About